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At a recent quarterly review meeting of a major diagnostic
company, one of the senior executives was questioning the
Director of Research and Development. Why haven't you
discovered any new cancer biomarkers despite million of
dollars spent? When are you going to give us some new
cancer proteomic diagnostics? If not, we are going to stop
funding your proteomics program very soon. Similar
questions were also asked at a government-funded program
review meeting.
The question is “will cancer proteomics suffer from
premature death?”
My view is that these people are shortsighted. Finding
clinically useful cancer biomarkers is not easy. However,
the potential impact on the clinical outcome of cancer
patients could be fairly significant. Most people do not
appreciate that the time frame for biomarker discovery,
verification, validation, and translation into clinical practice
is a long and difficult process.
Is the development of cancer proteomic diagnostics
worthy of the investment?
First, let us look at the tremendous opportunities of
cancer biomarkers in personalized medicine. Biomarkers
can be used for the early detection of cancer, which could
save life. Biomarkers can also be used in the assessment of
cancer risk and in the monitoring of cancer development in
a targeted high-risk population. They can be used in
differential diagnosis and tumor staging to improve clinical
accuracy and in the prognosis of clinical outcome. They can
also be used to guide targeted therapy, which will improve
the efficacy of treatment modality and generate less
toxicity. Finally, they can be used to monitor responses of
therapy and in the detection of cancer recurrence. This
could improve patient survival.
Why haven't we taken advantage of these opportunities?
Currently, there are less than two dozen cancer proteomic
biomarkers cleared or approved by the FDA in the United
States for clinical use [1]. Furthermore, these biomarkers
have significant limitations. Most of these biomarkers are
for monitoring therapy. Few cancer biomarkers are for
predicting therapy or prognosis. Only the prostate-specific
antigen (PSA) is approved for the early detection of cancer.
No biomarkers have been approved for cancer screening in
a general population.
Why haven't we developed more cancer proteomic
diagnostics to meet the clinical needs?
In the field of proteomics, discovery research in finding
candidate biomarkers is relatively easy, as evident by the
large number of biomarkers published in the scientific
literature. However, the validation process in selecting
biomarkers with consistent clinical significance in a general
population is much more difficult. Few candidate bio-
markers survive the validation step. Finally, the translation
of these biomarkers into clinical diagnostics which could
meet clinical and regulatory requirements is often time-
consuming and costly.
There are significant obstacles in proteomics biomarker
research. The first issue is the complexity of the plasma
proteome with the extreme dynamic ranges of protein
concentration in the order of 1010 and the constant
changing of the proteomic profiles with varying conditions,
such as significant biological variability among individuals
within the same population and the specimen integrities in
their collection, processing, storage, and stability. The two
major technologies used in proteomics research have
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limitations. Mass spectrometry has limited sensitivity and
requires extensive fractionation. Protein microarrays are a
targeted approach in the detection of a limited number of
proteins. We need standards or reference materials for
comparison among different instruments or technologies as
well as better study design to minimize systemic biases
from non-disease-associated factors and standard operating
procedures for proteomics studies. In the processing of
proteomic data, we should minimize data processing error
and over-fitting of high dimensional data (pattern recogni-
tion). In addition, there is no consensus among different
groups for the requirements or performance characteristics for
cancer diagnostics and no standard procedure exists for the
development of cancer biomarkers into clinical diagnostics.
Why aren't we making more progress than expected in
cancer proteomics?
Let's hear what these people had to say during a recent
fund-raising reception for cancer research.
“I want to have testing for this new cancer biomarker that I
read about on the internet,” says a patient. “However, when I
asked my doctor, the doctor had never even heard of it.”
An oncologist says, “from my point of view, most of
these cancer biomarkers are non-specific. When the test is
‘positive’, I don't know what to do with it! It often
generates more unnecessary testing. What I really want
are predictive biomarkers for directing therapies.”
A VP of new business development from a major
diagnostic company says “I don't see any real winners
(cancer biomarkers) to license. Even if I found one, the cost
of developing cancer diagnostics, conducting a clinical
study and obtaining FDA approval is just too time-
consuming and costly.”
A cancer researcher from a nearby well-known univer-
sity says “my NIH grant only covers the discovery of
biomarkers, not their validation or clinical studies. It is
someone else's job to do the follow-up work. My academic
promotion is dependent on publishing scientific articles in
high-impact journals only.”
A regulatory scientist from the Center for Devices and
Radiological Health branch of the US FDA says “the
submission document of the cancer biomarker test is
terrible. This manufacturer obviously doesn't know what
they are doing. The ‘intended use’ does not make any
sense. The study population does not match the clinical
intended use. There are insufficient data for the analytical
and clinical validations. How can we approve such a poor
submission for a cancer diagnostic test device?”
A manager of the Pathology Core Lab from a nearby
teaching hospital says “I would love to offer this new cancer
test, but the cost of the reagent kit/instrument and technical
time is just too expensive for the amount of reimbursements.”
Finally, a mid-level executive from an insurance company
says “cancer biomarkers, in general, are not cost effective.
Give me some evidence-based laboratory medicine before I
can agree to any reimbursements.”
What should we do?
First, we should define what biomarkers are needed
clinically. Then, we could select those biomarkers that are
promising for the development of cancer diagnostics. We
need to create a team consisting of key players in the
discovery, validation, development, approval, reimburse-
ment, and use of cancer diagnostics. This would include
researcher, clinician, diagnostics developer, and regulator
from academia, government, and industry. We need to
develop a consensus process and construct a roadmap for
the development of in vitro cancer diagnostics. Technologies
such as mass spectrometry and protein/lectin microarrays are
useful technologies for proteomic biomarker discovery. For
routine analysis of cancer diagnostics, an automated multi-
plex immunoassay platform might be more suitable. The key
is to identify biomarkers with clinical potentials for the early
detection and/or prognosis of cancer, followed by analytical
and clinical validations of these biomarkers using well-
characterized standard reference materials and targeted
patient populations. The translation of cancer biomarkers
will be facilitated via public–private partnerships and
collaborative research networks, such as the National Cancer
Institute Early Detection Research Network (NCI EDRN).
Finally, here is a recent “success story” of cancer
proteomic diagnostics.
On March 9, 2010, The Wall Street Journal reported a
Test to Help Determine If Ovarian Masses Are
Cancer. Doctors and hospitals are getting a new test
that many think will help fight ovarian cancer, one of
the deadliest cancers, by helping them to more
quickly distinguish cancerous from benign growths.
The test, which is called OVA1 and will be available
for general use Tuesday, was shown to correctly flag
92% of cancers, when used along with radiological
imaging and a standard patient work-up, in a study of
27 hospitals, doctors' offices and clinics. Physicians
using their usual detection methods but not OVA1 had
previously found 72% of the cancers. ‘It is an
amazing move forward,’ says Cara Tenenbaum, Vice
President of Policy for the ovarian cancer national
alliance, a nonprofit patient advocacy group.
OVA1 is the first proteomics in vitro diagnostic
multivariate index assays (IVDMIA) cleared by the US
FDA for clinical use. It is based on two studies published in
2002 and 2004 [2, 3] from our laboratory and licensed to
Vermillion Inc. A detailed story of the development of this
cancer diagnostics can be found in an interesting article
written by Eric Fung [4] “A recipe for proteomics
diagnostic test development: The OVA1 test, from bio-
marker discovery to FDA clearance.”
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These are my final thoughts. Cancer will continue to be a
major disease for many years to come. Early detection and
prevention using cancer biomarkers will be the key to
improving cancer survival. Cancer biomarkers will be even
more important as more effective targeted therapies become
available. Instead of cancer proteomics suffering from
premature death, I believe that cancer biomarkers will be
the driving force in the war against cancer. We should
increase our efforts and funding in the area of research and
development for cancer proteomic biomarkers. As I said
earlier, the translation of cancer biomarkers into diagnostics
will be facilitated with public–private partnership and a
collaborative research network, such as the NIH/NCI
EDRN program.
References
1. Sokoll LJ, Chan DW. Biomarkers for cancer diagnostics. In:
Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna
WG, editors. Abeloff's clinical oncology. 4th ed. Philadelphia:
Elsevier; 2008. p. 277–82.
2. Rai AJ, Zhang Z, Rosenzweig J, Shih I-M, Pham T, Fung E, et al.
Proteomic approaches to tumor marker discovery: identification of
biomarkers for ovarian cancer. Arch Pathol Lab Med. 2002;126:
1518–26.
3. Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three
biomarkers identified from serum proteomics analysis for the
detection of early stage ovarian cancer. Cancer Res. 2004;64:5882–
90.
4. Fung ET. A recipe for proteomics diagnostic test development: the
OVA1 test, from biomarker discovery to FDA clearance. Clin
Chem. 2010;56(2):327–9.
Clin Proteom (2010) 6:1–3 3
